CAMP4 Therapeutics Corp

CAMP

3.840USD

+0.250+6.96%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

CAMP4 Therapeutics Corp's Score

Industry at a Glance

Industry Ranking

101 / 392

Overall Ranking

230 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

CAMP4 Therapeutics Corp Highlights

StrengthsRisks

CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

Growing

The company is in a growing phase, with the latest annual income totaling USD 652.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 652.00K.

Fairly Valued

The company’s latest PE is -1.56, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 1.67M shares of this stock.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.750

Target Price

+143.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of CAMP4 Therapeutics Corp is 7.51, ranking 105 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.51

Change

0



Financials

9.13

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.76

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.12

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of CAMP4 Therapeutics Corp is 7.81, ranking 79 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.56, which is -66.91% below the recent high of -0.52 and -184.78% above the recent low of -4.45.

Score

Industry at a Glance

Previous score

7.81

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 101/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of CAMP4 Therapeutics Corp is 8.67, ranking 70 out of 392 in the Biotechnology & Medical Research industry. The average price target is 7.50, with a high of 12.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of CAMP4 Therapeutics Corp is 6.85, ranking 151 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.79 and the support level at 2.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.71

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of CAMP4 Therapeutics Corp is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 24.28%, representing a quarter-over-quarter decrease of 56.99%. The largest institutional shareholder is The Vanguard, holding a total of 1.67M shares, representing 3.22% of shares outstanding, with 178.04% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

5AM Ventures

5.87M

+100.45%

Coastlands Capital LP

4.89M

--

Janus Henderson Investors

4.64M

--

Polaris Partners

3.93M

+49.80%

Vivo Capital, LLC

3.92M

--

Enavate Sciences GP, LLC

3.13M

-17.39%

Fidelity Management & Research Company LLC

3.02M

+397.32%

Northpond Ventures, LLC

2.24M

--

Andreessen Horowitz

2.13M

--

Adage Capital Management, L.P.

1.96M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CAMP4 Therapeutics Corp is 1.66, ranking 295 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. CAMP4 Therapeutics Corp’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

CAMP4 Therapeutics Corp

CAMP

6.62 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment